Related Experiment Video

Updated: May 15, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis

Saurav Chatterjee1, Giuseppe Biondi-Zoccai, Antonio Abbate

  • 1Division of Internal Medicine, Maimonides Medical Center, New York, NY, USA. sauravchatterjeemd@gmail.com

BMJ (Clinical Research Ed.)
|January 18, 2013
PubMed

Insights

Beta blockers offer significant mortality benefits for heart failure with reduced ejection fraction. However, current evidence suggests these benefits are a class effect, with no single beta blocker proving superior.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Heart failure with reduced ejection fraction (HFrEF) is a significant cause of mortality.
  • Beta blockers are a cornerstone therapy for HFrEF, but their comparative efficacy is debated.

Purpose of the Study:

  • To determine if specific beta blockers offer superior outcomes in HFrEF patients.
  • To ascertain whether the benefits of beta blockers in HFrEF are attributable to a class effect.

Main Methods:

  • Systematic review and network meta-analysis of randomized controlled trials.
  • Inclusion of trials comparing beta blockers against each other or placebo/standard treatment.
  • Primary endpoint: all-cause mortality; secondary endpoints: sudden cardiac death, pump failure death, drug discontinuation, and ejection fraction improvement.

Main Results:

  • 21 trials involving atenolol, bisoprolol, bucindolol, carvedilol, metoprolol, and nebivolol were analyzed.
  • Beta blockers demonstrated significant mortality benefits compared to placebo (OR 0.69).
  • No significant differences were observed between individual beta blockers regarding mortality, cardiac death, pump failure, discontinuation, or ejection fraction improvements.

Conclusions:

  • The mortality benefits of beta blockers in HFrEF appear to be a class effect.
  • Current evidence does not support the superiority of any single beta blocker over others in this patient population.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...